Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Janssen to acquire oncolytic virus company BeneVir

May 2, 2018 4:09 PM UTC

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) is acquiring oncolytic virus company BeneVir Biopharm Inc. (Rockville, Md.).

BeneVir shareholders will receive $140 million up front and are eligible for $900 million in milestones, according to majority shareholder HC2 Holdings (NYSE:HCHC). The deal is due to close this quarter...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article